Somewhat Critical Media Coverage Somewhat Unlikely to Affect Invivo Therapeutics (NVIV) Share Price

News coverage about Invivo Therapeutics (NASDAQ:NVIV) has trended somewhat negative on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invivo Therapeutics earned a daily sentiment score of -0.06 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.0197498162228 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Separately, ValuEngine lowered Invivo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Shares of Invivo Therapeutics (NVIV) traded down $0.06 during mid-day trading on Wednesday, reaching $0.82. The company had a trading volume of 533,900 shares, compared to its average volume of 261,827. Invivo Therapeutics has a 1-year low of $0.72 and a 1-year high of $4.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.06 and a quick ratio of 5.06.

Invivo Therapeutics (NASDAQ:NVIV) last issued its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). equities research analysts forecast that Invivo Therapeutics will post -0.81 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Critical Media Coverage Somewhat Unlikely to Affect Invivo Therapeutics (NVIV) Share Price” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/12/20/somewhat-critical-media-coverage-somewhat-unlikely-to-affect-invivo-therapeutics-nviv-share-price.html.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply